Evidence check: FTO in the context of Abnehmen

The FTO gene is the most robustly replicated obesity locus from genome-wide association studies. Carriers of the risk allele (e.g., rs9939609) have a modestly higher BMI (≈0.3–0.5 kg/m² per allele) and increased obesity risk. However, the effect size is small and explains only a tiny fraction of population weight variance. In weight‑loss interventions, FTO genotype does not reliably predict success: meta-analyses show no significant difference in weight change between risk and non‑risk carriers. The proposed mechanism involves altered appetite regulation (e.g., higher ghrelin, reduced satiety), but evidence is largely observational. Crucially, having the risk allele does not prevent weight loss; lifestyle factors (caloric deficit, physical activity) are far more decisive. Commercial DNA tests often overstate FTO’s impact. For consumers, the take‑home message is that FTO status should not drive major dietary changes. Evidence is strong for association but weak for clinical utility in weight management.